Oral Tirzepatide: What We Know About the Pill Form of Mounjaro and Zepbound
Eli Lilly's oral tirzepatide is in late-stage clinical trials. Here's the current status, expected timeline, and how it might compare to oral semaglutide.
What oral tirzepatide is
Tirzepatide is the active ingredient in Mounjaro (for Type 2 diabetes) and Zepbound (for weight management). It’s a dual GIP/GLP-1 receptor agonist — meaning it activates two gut hormone receptors instead of one, which is thought to contribute to its superior weight loss results compared to semaglutide. Currently, tirzepatide is available only as a weekly injection. Eli Lilly is developing an oral formulation.
Where development stands
Oral tirzepatide is in Phase 3 clinical trials as of 2026. Eli Lilly has not announced a specific FDA submission timeline, but analysts expect a potential filing in late 2026 or 2027, with approval and launch potentially in 2027 or 2028. These timelines are speculative and subject to change based on trial results and regulatory review.
The GIP/GLP-1 advantage
Injectable tirzepatide has demonstrated greater average weight loss than injectable semaglutide in head-to-head trials. The SURMOUNT program showed up to 22.5% body weight reduction with the highest injectable tirzepatide dose — compared to approximately 15% with injectable semaglutide. If the oral form preserves this advantage, it would represent the most potent oral weight loss medication available.
Whether the dual-agonist advantage translates to the oral form depends on achieving adequate bioavailability — the same challenge that oral semaglutide addresses with SNAC technology. Eli Lilly’s oral delivery approach has not been fully disclosed publicly.
What this means for patients today
Oral tirzepatide is not available today. Patients who are interested in tirzepatide currently need to use the injectable form. Patients who prefer an oral GLP-1 medication for weight management have one FDA-approved option: the Wegovy pill (oral semaglutide 25mg).
For patients seeking the most affordable GLP-1 access today, compounded injectable semaglutide through providers like Yucca Health or SHED offers the lowest price point, though compounded medications are not FDA-approved.
The competitive landscape
The oral GLP-1 market is expected to expand significantly over the next 2–3 years. In addition to oral tirzepatide, several other companies are developing oral GLP-1 and multi-agonist formulations. For patients, this competition is likely to drive prices down and expand access — but only after these products clear clinical trials and regulatory review.
Paid links · Providers we track
GLP-1 Providers We Track
| Provider | Category | Starting | |
|---|---|---|---|
| Sesame Care | GLP-1 (brand) | from $199 | View Provider → |
| Yucca Health | GLP-1 | from $149/mo | View Provider → |
| Embody | GLP-1 | $400 CPA | View Provider → |
| SHED | GLP-1 | from $199/mo | View Provider → |
| Novi | GLP-1 | $174/mo | View Provider → |
Compounded medications are not FDA-approved. Verify pricing on provider’s site before enrolling.
How we evaluate: Oral GLP-1s reviews providers based on licensing, pricing transparency, clinical quality, and patient experience. We earn commissions from some providers, which does not influence our coverage. Full methodology →
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved. Consult a licensed clinician before starting any treatment.